Lupin says VISUfarma acquisition now expected to close by February 28

Drug firm Lupin Ltd on Tuesday (December 30) said the acquisition of Amsterdam-based VISUfarma BV is in progress and may be completed by February 28, 2026, subject to certain closing conditions.

In an update

on the transaction, the company recalled that it had earlier informed on September 29, 2025, that Nanomi BV, a wholly-owned subsidiary of Lupin, had entered into a definitive agreement to acquire the entire share capital of VISUfarma BV, headquartered in Amsterdam.

At that time, Lupin had indicated that the transaction would be consummated by the end of the calendar year 2025.

Yesterday (December 29), Lupin said it has entered into an exclusive licence, supply, and distribution agreement with Gan & Lee Pharmaceuticals, headquartered in China, for bofanglutide, a novel fortnightly GLP-1 receptor agonist.

Also Read: Lupin shares gain ahead of US drug launch that can fetch $200 million in FY26

The agreement is aimed at strengthening Lupin’s diabetes portfolio and expanding its presence in the obesity segment. Bofanglutide injection, developed by Gan & Lee, is designed for adults with type 2 diabetes and also assists in weight management for overweight or obese individuals.

As a potential first-in-class global fortnightly GLP-1 agonist, clinical data demonstrate that the weight loss results of bofanglutide are comparable to or better than those of existing GLP-1 alternatives while offering the convenience of once every two weeks versus once a week for other injectable alternatives, and maintaining safety and tolerability consistent with the GLP-1 class. It effectively reduces both blood glucose levels and body weight.

Obesity is anticipated to develop into a significant health crisis in India, with approximately 174 million adults classified as overweight and around 50 million as obese. Diabetes is already considered an epidemic, with approximately 90 million adults affected by the condition. Under the terms of the agreement, Lupin will have exclusive rights to commercialise and distribute bofanglutide in India.

Also Read: Lupin's Nagpur injectable facility secures US FDA VAI classification

Shares of Lupin Ltd ended at ₹2,080.40, down by ₹1.70, or 0.082%, on the BSE today, December 30.